UMIN-CTR History

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Unique ID issued by UMIN UMIN000010582
Receipt No. R000012367
Scientific Title Multicenter phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320)
Date of disclosure of the study information 2013/04/26
Last modified on 2020/11/12 10:43:39

No. Disposal Last modified on Item of update
1 Insert 2013/04/24 13:45:41
2 Update 2013/10/24 09:59:51 Email
Email
3 Update 2014/05/26 10:31:54 Email1
4 Update 2014/07/18 10:40:34 Email
5 Update 2015/04/27 15:06:38 Public title
Public title
Acronym
Acronym
6 Update 2015/04/27 15:08:08 Narrative objectives1
Narrative objectives1
7 Update 2015/04/27 15:16:39 Key inclusion criteria
Key inclusion criteria
Key exclusion criteria
Key exclusion criteria
8 Update 2016/04/25 08:57:53 Name of primary sponsor
Organization
9 Update 2016/04/25 09:27:22 Control
Interventions/Control_1
Interventions/Control_1
10 Update 2016/08/16 10:03:52 Recruitment status
Last follow-up date
11 Update 2018/05/17 09:25:09 Date analysis concluded
12 Update 2019/04/24 09:25:58 Recruitment status
Date of IRB
Anticipated trial start date
13 Update 2020/11/12 10:43:39 URL releasing protocol
Publication of results
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results
Results date posted
Baseline Characteristics
Baseline Characteristics
Participant flow
Participant flow
Adverse events
Adverse events
Outcome measures
Outcome measures


Contact us.